Ardelyx reports Q3 net income $6.6M; IBSRELA sales $22.3M; raises FY guidance to $76-78M

ARDELYX, INC.

2023-Q3 EPS reported -$0.17 revenue$90,093,000

Q3 net income $6.6M ($0.03/share) vs net loss $22.9M in Q3 2022; total revenue $56.4M vs $5.0M.
IBSRELA U.S. net sales $22.3M (22% QoQ growth); FY 2023 guidance raised to $76-78M.
XPHOZAH FDA approved Oct 17, 2023; commercial launch underway, product in channel early Nov.
Cash, cash equivalents & short-term investments $165.1M at Sep 30; ~$218.1M as of Oct 30.
Received $30M milestone from Kyowa Kirin for Japan approval; drew $22.5M from SLR loan amendment.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

ARDELYX, INC. updated its the third quarter ended September 30, 2023 guidance (reaffirmed).

Period: the third quarter ended September 30, 2023
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On October 31, 2023, Ardelyx, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2023.

View on SEC.gov

Browse all earnings releases →

ARDELYX, INC. filing history →

Source: SEC EDGAR

accession 0001628280-23-035596

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.